Horizon Pharma Inc (HZNP) 13.78 $HZNP INVESTOR NOTICE:

New Post Public Reply Private Reply Replies (0) Message Board

Oct 22, 2015 at 1:17 PM

Horizon Pharma Inc (HZNP) 13.78 $HZNP

INVESTOR NOTICE: Khang & Khang LLP Announces An Investigation Of Claims Against Horizon Pharma plc And Advises Shareholders To Contact The Firm
Business Wire - 2 hrs 47 mins ago
Khang & Khang LLP announces that it is investigating claims of potential misrepresentations by Horizon Pharma plc ("Horizon" or the "Company"

(NASDAQ: HZNP). The investigation focuses on whether the Company and its officers violated securities laws by issuing misleading information to investors.
HZNP: 13.78 (-1.05)

SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Horizon Pharma plc
PR Newswire - Thu Oct 22, 9:00AM CDT
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of the securities of Horizon Pharma plc ("Horizon" or the "Company"

(NasdaqGS: HZNP -News). Such investors are advised to contact Peretz Bronstein or his investor relations coordinator Eitan Kimelman at info@bgandg.com or 212-697-6484.
HZNP: 13.78 (-1.05)

Covered Call Alerts For Chipotle Mexican Grill, Horizon Pharma, Abbott Laboratories, Bank of America and Amgen Released By InvestorsObserver
PR Newswire - Thu Oct 22, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for CMG, HZNP, ABT, BAC and AMGN.
ABT: 42.94 (+0.74), CMG: 658.35 (-7.32), HZNP: 13.78 (-1.05), AMGN: 151.80 (+1.71), BAC: 16.14 (+0.24)

Depomed Comments on Recent Reports Regarding Horizon Pharma's Business Model
PR Newswire - Thu Oct 22, 7:30AM CDT
Depomed, Inc. (NASDAQ: DEPO) ("Depomed" or the "Company"

today issued the following statement in response to numerous recent reports surrounding Horizon Pharma plc's (NASDAQ: HZNP) ("Horizon"

business model, in particular concerns raised about aggressive drug pricing practices and Horizon's use of specialty pharmacies:
HZNP: 13.78 (-1.05), DEPO: 15.42 (-0.70)

Horizon Pharma plc Announces the U.S. Patent and Trademark Office Issuance of an Additional Notice of Allowance With Claims Covering PENNSAID(R) (diclofenac sodium topical solution) 2%
Marketwired - Thu Oct 22, 6:00AM CDT
Horizon Pharma plc (NASDAQ: HZNP), a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs, today announced it received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for U.S. patent application number 14/705,649 (U.S. publication number 2015-0231264), entitled "Diclofenac Topical Formulation" that covers Horizon's U.S. approved product PENNSAID(R) (diclofenac sodium topical solution) 2% w/w (PENNSAID 2%).
HZNP: 13.78 (-1.05)

Horizon Pharma plc Provides Update on Relationship With Specialty Pharmacies
Marketwired - Wed Oct 21, 4:55PM CDT
Horizon Pharma plc (NASDAQ: HZNP), a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs, today provided an update on its relationship with specialty pharmacies:
HZNP: 13.78 (-1.05)

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Horizon Pharma plc - HZNP
ACCESSWIRE - Wed Oct 21, 4:46PM CDT
NEW YORK, NY / ACCESSWIRE / October 21, 2015 / Pomerantz LLP is investigating claims on behalf of investors of Horizon Pharma plc ("Horizon" or the "Company"

(NASDAQ: HZNP). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 9980.
HZNP: 13.78 (-1.05)

IMPORTANT INVESTOR ALERT: Goldberg Law PC Announces An Investigation Of Claims Against Horizon Pharma plc And Encourages Investors To Contact The Firm
Business Wire - Wed Oct 21, 2:40PM CDT
Goldberg Law PC (http://www.Goldberglawpc.com) announces that it is investigating claims of potential misrepresentations by Horizon Pharma plc ("Horizon" or the "Company"

(NASDAQ: HZNP). The investigation focuses on whether the Company and its officers violated securities laws by issuing misleading information to investors.
HZNP: 13.78 (-1.05)

Horizon Pharmaceutical (HZNP) Stock Tumbles on Use of Specialty Pharmacies
at The Street - Wed Oct 21, 1:27PM CDT
Horizon Pharmaceutical (HZNP) stock is declining in afternoon trading, as it and Valeant Pharmaceuticals are scrutinized for their use of specialty pharmacies.
HZNP: 13.78 (-1.05)

INVESTIGATION ALERT: Rigrodsky & Long, P.A. Announces Commencement of an Investigation of Horizon Pharma plc for Possible Violations of Federal Securities Laws
PR Newswire - Wed Oct 21, 1:06PM CDT
Rigrodsky & Long, P.A.:
HZNP: 13.78 (-1.05)

Targets of Market Hatred Can Change Daily
at The Street - Wed Oct 21, 12:03PM CDT
It used to be industrials, now it's health care.
TSLA: 213.67 (+3.58), VRX: 100.17 (-18.44), GE: 29.67 (+0.82), CLX: 123.37 (+1.31), VMW: 56.19 (+0.77), NKE: 131.32 (-1.15), HON: 102.61 (+3.84), UTX: 100.03 (+2.06), WMT: 58.91 (+0.27), INTC: 34.38 (+1.01), SLB: 78.19 (+2.56), K: 71.20 (+1.59), SBUX: 61.47 (+0.94), CMG: 658.35 (-7.32), HZNP: 13.78 (-1.05), COST: 157.21 (+2.00), EMC: 25.89 (+0.12), CRZO: 37.97 (-0.12), PPG: 103.29 (+2.65), BHI: 55.96 (+1.55), ETN: 54.80 (+2.28), SWKS: 80.94 (+3.27), HAL: 39.89 (+1.49), HRL: 67.99 (+1.38), NXPI: 95.46 (+4.14), BA: 146.78 (+5.59), WDC: 71.24 (-0.20), NFLX: 98.09 (+0.13), LB: 97.04 (+0.52), LRCX: 72.66 (+1.87), GM: 35.48 (+0.06), MCD: 110.31 (+7.77), DOV: 64.21 (+2.33), KLAC: 65.08 (+1.10), AVGO: 124.86 (+4.36), SNDK: 76.88 (+0.10)

Horizon Pharma plc Announces Favorable Markman Ruling in RAVICTI(R) (glycerol phenylbutyrate) Oral Liquid Patent Infringement Lawsuit
Marketwired - Wed Oct 21, 6:00AM CDT
Horizon Pharma plc (NASDAQ: HZNP), a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs, today announced that a favorable Markman ruling has been issued by Judge Roy Payne in the United States District Court for the Eastern District of Texas Marshall Division in the patent infringement lawsuit filed by Horizon against Par Pharmaceutical, Inc. for an Abbreviated New Drug Application ("ANDA"

to market a generic version of RAVICTI.
HZNP: 13.78 (-1.05)

HZNP SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces the Commencement of an Investigation Involving Possible Securities Fraud Violations by Horizon Pharma plc and Certain Officers and Directors
Business Wire - Tue Oct 20, 3:39PM CDT
Levi & Korsinsky, LLP announces that it has commenced an investigation of Horizon Pharma plc ("Horizon Pharma" or the "Company"

(NASDAQGS:HZNP) concerning possible violations of federal securities laws by the Company and/or certain of its officers and directors.
HZNP: 13.78 (-1.05)

Jim Cramer -- Microsoft, IBM Should Have Their Eyes on the Buys
at The Street - Tue Oct 20, 1:20PM CDT
If you ask Jim Cramer (and social media users did), Microsoft should acquire Salesforce, IBM should grab Box, pharmaceuticals have a political problem, and there's no substitute for Berkshire Hathaway.
WFM: 32.95 (-0.03), VRX: 100.17 (-18.44), BOX: 12.84 (+0.20), TREE: 94.59 (+0.10), TFM: 26.03 (-0.61), PSTG: 19.15 (-0.10), WFC: 54.33 (+1.21), MKL: 869.99 (+19.99), WWAV: 40.92 (+0.55), RDUS: 61.59 (+0.14), LEN: 51.94 (-0.15), IBM: 144.43 (+3.51), HZNP: 13.78 (-1.05), WY: 29.99 (+0.77), MSFT: 48.73 (+1.53), TOL: 36.42 (-0.16), BRK.A: 204,960.00 (+5,060.00), CRM: 77.88 (+2.05)

Horizon Pharma plc to Host Third Quarter 2015 Conference Call and Webcast on November 6, 2015
Marketwired - Fri Oct 16, 6:00AM CDT
Horizon Pharma plc (NASDAQ: HZNP), a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs, announced today that its third quarter 2015 financial results will be released on Friday, November 6, 2015. Following the announcement, Horizon's management will host a live conference call and webcast at 8 a.m. Eastern Time to review the Company's financial and operating results.
HZNP: 13.78 (-1.05)

Horizon Pharma plc Files Definitive Proxy Statement for Extraordinary General Meeting of Horizon Pharma Shareholders
Marketwired - Thu Oct 15, 6:01AM CDT
Horizon Pharma plc (NASDAQ: HZNP) ("Horizon Pharma"

, a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs, today announced that it has filed a definitive proxy statement on Schedule 14A with the Securities and Exchange Commission ("SEC"

in connection with the extraordinary general meeting of Horizon Pharma shareholders (the "Meeting"

. The principal purpose of the Meeting is to approve the issuance of Horizon ordinary shares in connection with Horizon Pharma's proposed acquisition of Depomed, Inc.
HZNP: 13.78 (-1.05), DEPO: 15.42 (-0.70)

Three Canadian Biotechs with Pending Catalysts
ACCESSWIRE - Wed Oct 14, 11:02AM CDT
CORAL GABLES, FL / ACCESSWIRE / October 14, 2015 / In the rush of sector-wide biotech news, especially since Hillary Clinton's now infamous tweet that rocked the entire sector late last month, some developments that would have otherwise been big news may have gotten a bit lost in the ruckus. This is even more the case with foreign stocks that already receive less focus than US-based biotechs. Lest we lose sight of potential opportunities, here are three Canadian biotechs with catalysts pending.
HZNP: 13.78 (-1.05), TRIL: 13.50 (+0.19)

Horizon Pharma plc Files Preliminary Proxy Materials for Special Meetings
Marketwired - Tue Oct 13, 3:30PM CDT
Horizon Pharma plc (NASDAQ: HZNP) ("Horizon Pharma"

, a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs, today announced that it has filed preliminary proxy materials on Schedule 14A with the Securities and Exchange Commission ("SEC"

in connection with its solicitation of proxies to vote in favor of proposals at two related special meetings of Depomed, Inc. ("Depomed"

that Horizon Pharma is currently soliciting consents from Depomed shareholders to call one special meeting to remove all of the current Depomed directors and repeal a series of recent amendments to Depomed's bylaws (the "Removal and Bylaw Amendments Special Meeting"

and a second special meeting to elect replacement directors (the "Election Special Meeting"

.
HZNP: 13.78 (-1.05), DEPO: 15.42 (-0.70)

Timothy P. Walbert Joins Sucampo's Board of Directors
GlobeNewswire - Tue Oct 13, 5:45AM CDT
Sucampo Pharmaceuticals, Inc. (Sucampo) (NASDAQ:SCMP), a global biopharmaceutical company, today announced that Timothy P. Walbert has joined Sucampo's Board of Directors. Mr. Walbert currently serves as Chairman, President and Chief Executive Officer of Horizon Pharma plc.
SCMP: 17.30 (+0.07), HZNP: 13.78 (-1.05)

Alcoa and Gap are big market movers
AP - Fri Oct 09, 3:26PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily Friday on the New York Stock Exchange and the Nasdaq Stock Market:
HELE: 98.98 (+0.49), AA: 9.26 (+0.15), HZNP: 13.78 (-1.05), ASNA: 13.25 (+0.30), GPS: 27.42 (+0.44), APOL: 7.64 (-2.96)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Alaska's Insurance Maze: Coverage Over Cheap Policies

Beyond Premiums: Assessing Real Coverage Needs The Alaskan wilderness isn't just home to stunning views; it's also a land where insurance needs to go beyond the average cookie-cutter policy. You'd think the cheapest option would suffice, but that's where residents might trip into financial quicksand. Devery Prince, a seasoned insurance principal, sheds light on why...

Tony Perkins' Church Tour amid Controversial Vote

Lining the pews in Missouri and Kansas, folks are about to get a powerful dose of Tony Perkins this weekend. The Family Research Council President is driving straight into the heart of both spiritual and political fervor at a couple of church stops on Sunday, October 25—right on the doorstep of a crucial vote in Missouri. Taking the Stage in a Time of Tension Now,...

CapCut's AI Tools Reshape Video Content Creation

AI Revolution in Marketing Content: CapCut Takes Lead It's like the old guard of marketing has hitched a ride on a rocket. In 2026, CapCut has stomped into the limelight with Better Business Advice giving them a nod for their prowess in AI-driven content creation. This isn't some passing trend; it's a seismic shift in how businesses craft their messages. CapCut ain't just...

What to Expect: Your First Therapy Session Insights

Starting With the Unknown: The Therapy Journey Begins Rolling into that first therapy session can feel like walking into a mystery with no clues. You're not alone if it stirs up some nerves—most folks feel the same, especially when it's your first rodeo in mental health support. That's where Cody Luke and David Spencer of Luke and Spencer Behavioral Health, based out in...

Duolingo Faces Class Action: Deadline Looms for Plaintiffs

Shaking up the education sector like a hot potato, investors have been thrown for a loop with Duolingo’s latest legal debacle. News broke that Kahn Swick & Foti, LLC, with significant backing from their heavyweight partner and former Louisiana Attorney General Charles C. Foti Jr., is spearheading a class action lawsuit against Duolingo, Inc. (NasdaqGS: DUOL). It’s one...

COhatch Preps for High-Stakes Ohio Pitch Contest

Ohio Startups Gear Up for Another Fierce Faceoff You wouldn't find me betting against a hungry entrepreneur, especially with $25,000 on the line. That's the prize dangling at this year's Dublin Pitch Competition, hosted by COhatch and the City of Dublin. If there's one thing I'm certain of, it's that Ohio will see some real contenders stepping up on October 15....

Chemours Faces Class Action Over Fraud Allegations

Chemours and the Aftermarket Mirage When it rains, it pours, and for Chemours, the forecast isn't looking sunny. Investors are gearing up to slap Chemours Company (NYSE: CC) with a securities fraud class action. Why, you ask? Overstatement of aftermarket demand for refrigerants left investors high and dry after stock prices took an 18% nosedive. On August 4, 2026,...

Axon Body 5: A Leap Forward in AI for Public Safety

Axon Raises the Stakes with Body 5 Camera Boy, oh boy, Axon's dropped a bombshell with the Body 5. We're talking a colossal leap into the AI era for public safety, and if you're in the biz, you can't just shrug this one off. We're looking at 25 times the AI processing power compared to Axon's old units. That's right, I said twenty-five. Real-time situational awareness in...

Gildan Faces Lawsuit: Allegations of Deceptive Practices Shake Investors

Gildan's Troubles Unveiled The financial jungle can be a pretty treacherous place, and Gildan Activewear Inc. (NYSE: GIL) just found out how fickle the market can be. An 18.7% nosedive in Gildan's stock price after a securities fraud class action came knocking—if that isn't enough to stir up a hornet’s nest among investors, I don’t know what is. The Catalyst:...

Lunit, Summit Tackle Tumor Analysis with AI Platform

Amid whispers of AI revolutionizing every industry, let's zero in on its latest pit stop—oncology R&D. Lunit, shaking hands with Summit Therapeutics, plans to bring artificial intelligence into the tumor microenvironment analysis game, thanks to the Lunit SCOPE IO platform. This isn't just another lab experiment; it's a step towards redefining how we understand cancer's...